Evaluation of Glycemic Variability in Well-controlled Type 2 Diabetes Mellitus
Overview
Pharmacology
Authors
Affiliations
Aims: It is necessary to evaluate glucose variability and postprandial hyperglycemia in patients with well-controlled type 2 diabetes mellitus because of the limitations associated with hemoglobin A1c (HbA1c) measurements. We evaluated parameters reflecting postprandial hyperglycemia and glycemic variability in patients with optimal HbA1c.
Patients And Methods: Thirty-nine patients with HbA1c levels below 7% were recruited to the study. A continuous glucose monitoring system (CGMS) was applied for two 72-h periods. 1,5-Anhydroglucitol (1,5-AG) and fructosamine (FA) were measured as parameters for postprandial hyperglycemia and glucose variability. Using CGMS data, the following postprandial hyperglycemia parameters were calculated: mean postprandial maximum glucose (MPMG) and area under the curve for glucose above 180 mg/dL (AUC-180). To measure glycemic variability, we calculated mean amplitude of glucose excursion (MAGE) using a classical (MAGEc) and new method (MAGE group of sign [MAGEgos]).
Results: The baseline HbA1c level was 6.3±0.3%. The mean MPMG was 10.34±1.84 mmol/L, and the mean AUC-180 was 0.17±0.23 mmol/L/day. The mean MAGEgos was 3.27±1.29 mmol/L, and MAGEc was 4.30±1.43 mmol/L, indicating glycemic variability in our patients. The mean levels of 1,5-AG and FA were 16.7±7.4 μg/mL and 273.0±22.5 μmol/L, respectively. In a correlation analysis, FA was significantly correlated with MPMG, AUC-180, MAGEgos, and MAGEc. In contrast, 1,5-AG was only correlated with AUC-180.
Conclusions: This study demonstrated postprandial hyperglycemia and glycemic variability in subjects with well-controlled diabetes. FA may reflect postprandial hyperglycemia and glycemic variability, but 1,5-AG may be of limited value for assessing glucose variability in patients with well-controlled type 2 diabetes mellitus.
Santoso A, Destra E, Firmansyah Y, Lontoh S J Multidiscip Healthc. 2025; 18:1393-1404.
PMID: 40066249 PMC: 11892493. DOI: 10.2147/JMDH.S486370.
Andonova M, Dzhelebov P, Trifonova K, Yonkova P, Kostadinov N, Nancheva K Vet Sci. 2023; 10(7).
PMID: 37505836 PMC: 10386364. DOI: 10.3390/vetsci10070431.
Lin X, Li Q, Zhao D, Liu J, Fan Q Front Cardiovasc Med. 2022; 9:943185.
PMID: 36237913 PMC: 9551162. DOI: 10.3389/fcvm.2022.943185.
Assessment of glycemia in chronic kidney disease.
Hassanein M, Shafi T BMC Med. 2022; 20(1):117.
PMID: 35414081 PMC: 9006428. DOI: 10.1186/s12916-022-02316-1.
Breyton A, Lambert-Porcheron S, Laville M, Vinoy S, Nazare J Front Endocrinol (Lausanne). 2021; 12:666008.
PMID: 34566883 PMC: 8458933. DOI: 10.3389/fendo.2021.666008.